Regeneron Pharmaceuticals (REGN - Get Report) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. This stock is trading up 5.7% at $161.83 in recent trading.
Today's Volume: 1.2 millionAverage Volume: 731,583 Volume % Change: 219% Shares of REGN are spiking higher today after the company reported third-quarter results that far exceeded Wall Street estimates as it won key new approvals for its eye drug Eylea and cancer drug Zaltrap. From a technical perspective, REGN is ripping higher here right around its 50-day at $149.74 with above-average volume. This move is quickly pushing REGN within range of triggering a major breakout trade. That trade will hit once REGN manages to take out some near-term overhead resistance levels at $165 to $166.39 with high volume. Traders should now look for long-biased traders in REGN as long as its trending above its 50-day, and then once it sustains a move or close above those breakout levels with volume that hits near or above 731,583 shares. If that breakout triggers soon, then look for REGN to trend well north of $170. To see more stocks rising on unusual volume, check out the Stocks Rising on Unusual Volume portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.
Twitter and become a fan on Facebook.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts